Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone

Seminars in Oncology

Volumn 30, Issue 2, 2003, Pages 265-269

  Dimopoulos, M A ^a,b,c   Tsatalas, C ^a,b,c   Zomas, A ^a,b,c   Hamilos, G ^a,b,c   Panayiotidis, P ^a,b,c   Margaritis, D ^a,b,c   Matsouka, C ^a,b,c   Economopoulos, T ^a,b,c   Anagnostopoulos, N ^a,b,c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^c IASO GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; DEXAMETHASONE; THALIDOMIDE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; CUSHING SYNDROME; DRUG RESPONSE; EDEMA; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; LOW DRUG DOSE; MONOTHERAPY; MUCOSA INFLAMMATION; MUSCLE WEAKNESS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; SALVAGE THERAPY; SOMNOLENCE; STOMACH MUCOSA INJURY; THROMBOSIS; TREMOR; WALDENSTROEM MACROGLOBULINEMIA;

EID: 0037397379     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2003.50079     Document Type: Article

References (25)

1. Harris NL, Jaffe ES, Diebold, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999
2. Kyle RA, Garton JP: The spectrum of IgM monoclonal gammopathy in 430 cases. Mayo Clin Proc 62:719-731, 1987
3. Dimopoulos MA, Alexanian R: Waldenstrom's macroglobulinemia. Blood 83:1452-1459, 1994
4. Dimopoulos MA, Panayiotidis P, Moulopoulos LA: Waldenstrom's macroglobulinemia: Clinical features, complications and management. J Clin Oncol 18:214-226, 2000
5. Kyle RA, Greipp PR, Gertz MA, et al: Waldenstrom's macroglobulinemia: A prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol 108:737-742, 2000
6. Dimopoulos MA, Kantarjian H, Weber D, et al: Primary therapy of Waldenstrom's macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol 12:2694-2698, 1994
7. Dhodapkar MV, Jacobson JL, Gertz MA, et al: Prognostic factors and response to fludarabine therapy in patients with Waldenstrom's macroglobulinemia: Results of United States intergroup trial. Blood 98:41-48, 2001
8. Dimopoulos MA, Zervas C, Zomas A, et al: Treatment of Waldenstrom's macroglobulmemia with rituximab. J Clin Oncol 20:2327-2333, 2002
9. Singhal S, Mehta J, Desikan R, et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571, 1999
10. Dimopoulos MA, Zomas A, Viniou NA, et al: Treatment of Waldenstrom's macroglobulinemia with thalidomide. J Clin Oncol 19:3596-3601, 2001
11. Coleman M, Leonard JP, Michaeli J, et al: Biaxin, low-dose thalidomide, and dexamethasone for the treatment of myeloma and Waldenstrom's macroglobulinemia. Leuk Lymphoma 43:1777-1782, 2002
12. Richardson P, Hideshima T, Anderson K: Thalidomide: Emerging role in cancer medicine. Ann Rev Med 53:629-657, 2002
13. Raje N, Anderson K: Thalidomide - A revival story. N Engl J Med 341:1606-1609, 1999
14. Rajkumar SV, Timm M, Mesa RA, et al: Effect of thalidomide on myeloma cell apoptosis and VEGF secretion. Blood 96:364a, 2000 (suppl 1, abstr 1574)
15. Weber DM, Rankin K, Gavino M, et al: Angiogenesis factors and sensitivity to thalidomide in previously untreated multiple myeloma. Blood 96:168a, 2000 (suppl 1, abstr 724)
16. Hideshima T, Chauhan D, Shima Y, et al: Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96:2943-2950, 2000
17. Morikawa K, Watabe H, Araake M, et al: Modulatory effects of antibiotics on cytokine production by human monocytes in vitro. Antimicrob Agents Chemother 40:1366-1370, 1996
18. Matsuoka N, Eguchi K, Kawakami A, et al: Inhibitory effect of clarithromycin on costimulatory molecule expression and cytokine production by synovial fibroblast-like cells. Clin Exp Immunol 104:501-508, 1996
19. Morikawa K, Oseko F, Morikawa S, et al: Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin and clarithromycin on human T-lymphocyte function in vitro. Antimicrob Agents Chemother 38:2643-2647, 1994
20. Adachi T, Motojima S, Hirata A, et al: Eosinophil apoptosis caused by theophyline, glucocorticoids, and macrolides after stimulation with IL-5. J. Allergy Clin Immunol 98:207-215, 1996
21. Yatsunami J, Turuta N, Wakamatsu K, et al: Clarithromycin is a potent inhibitor of tumour-induced angiogenesis. Res Exp. Med. 197:189-197, 1997
22. Durie B.G.M, Villarete L, Farvard A, et al: Clarithromycin (Biaxin) as primary treatment for myeloma. Blood 90:579a, 1997 (suppl 1, abstr)
23. Moreau P, Huynh A, Facon T, et al: Lack of efficacy of clarithromycin in advanced multiple myeloma. Leukemia 13:490-491, 1999
24. Morris TCM, Ranaghan L, Morrison J: Phase II trial of clarithromycin and pamidronate therapy in myeloma. Med Oncol 18:79-84, 2001
25. Vescio RA, Sjak-Shie NN, Manyak SJ, et al: Clarithromycin adds to the efficacy and toxicity of steroid therapy in multiple myeloma. Blood 98:312b-313b, 2001